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Plasma lipids, including total cholesterol, low-density lipoprotein cholesterol (LDL-C), 64 high-density lipoprotein cholesterol (HDL-C), and triglycerides, are heritable risk factors for 65 atherosclerotic cardiovascular disease. 1,2 Understanding the inherited basis for plasma lipid 66 levels has led to new treatments and to tests to identify individuals at risk for disease. Advances 67 in technologies to characterize DNA sequence variants (i.e., Sanger sequencing, genotyping 68 arrays, exome sequencing) have progressively allowed us to solve monogenic forms of 69 dyslipidemia and to uncover common DNA sequence variants as well as rare mutations that 70 contribute to plasma lipid levels in the population. However, due to the inherent limitations of 71 genotyping arrays and exome sequencing, the non-coding regions of the genome remains 72 incompletely characterized, particularly for rare mutations. In addition, the relative contributions 73 of common DNA sequence variants and rare coding mutations to extreme lipid values has not 74 been delineated. 75
It is now possible to directly enumerate the whole genome sequences (WGS) of large 76 number of individuals. When performed at sufficient depth of coverage (>20-fold coverage per 77 base), WGS can detect single nucleotide polymorphisms, insertions, and deletions across the 78 allele frequency spectrum in both non-coding and coding regions. These advances allow us to 79 test the incremental value of WGS as a tool for locus discovery and also develop a framework to 80 understand why a specific individual might have an extreme lipid value. Towards these two 81 goals, we studied whole genome sequences in 16,324 participants of European, African, East 82
Asian, and Hispanic ancestries with available plasma lipids phenotypes. Estonian Biobank (EST) underwent WGS (Fig. 1) . Following Table  90 2). The mean (standard deviation) age was 51 (15) years and 8,669 (53%) were women. 5,911 91 (36%) of participants were of non-European ancestry ( Supplementary Table 2 Fig. 2) . The mean (standard deviation, SD) attained coverage 96 for >30X target samples was 37.1(5.4)X and for >20X target was 29.8(5.4)X. 97
After performing quality control, a total of 189 million unique variants were discovered 98 across all datasets. Total variant count characteristics varied by cohort due to sample sizes, 99 relatedness, ethnicity, and population history (Fig. 2) . As expected, the MESA cohort, of largely 100 unrelated individuals of four diverse ethnicities, had the most variants per individual while the 101 OOA cohort, a founder population of European ancestry, had the fewest variants per individual 102 (Supplementary Table 3 ). The median number of variants per individual was 3,391,000, of 103 which on average 4,878 were observed in only a single individual. 104 105
Common variant association study 106
We first analyzed common variants, i.e., those that occur often enough that it is practical to test 107 each variant individually. We considered variants that had MAF > 0.1% within at least one of the 108 three WGS variant callsets (minor allele count >16 for a callset that included FHS/OOA/JHS, >9 109 for MESA, and >6 for FIN and EST) ( Fig. 1) . We associated such variants with each of the four 110 plasma lipids within each callset and performed inverse-variance weighted meta-analysis. 111
Overall, 32,086,348 variants were included in this analysis. Systemic inflation was not observed 112
( Supplementary Table 4 and Supplementary Fig. 3A-D) . We used a conventional statistical 113 threshold for genome-wide significance (alpha = 5 x 10 -8 ) 3 (Supplementary Fig. 3E-H) . We 114 observed 592, 697, 447, and 522 variants associated with total cholesterol, LDL-C, HDL-C, and 115 triglycerides, respectively ( Supplementary Table 5 ). 116
These variants were distributed at 10, 7, 13, and 9 loci previously associated with total 117 cholesterol, LDL-C, HDL-C, and triglycerides, respectively, and 5 at putative novel lipid loci 118
( Supplementary Table 6 ). [4] [5] [6] [7] Of the variants at known loci, 12 (38.7%) were lead variants in 119 prior associations, 8 (25.8%) new lead variants were in high linkage disequilibrium (LD) (r 2 > 120 0.8) with prior lead variants, and the remaining 11 (35.5%) new lead variants were in low LD 121 with prior lead variants. 122
At a conventional alpha threshold of 5 x 10 -8 , we discovered 5 associations at putative 123 novel lipid loci ( Supplementary Table 6 ). For example, rs3215707 (MAF 2.0%), a 1-bp 124 deletion at 9p24.1, was associated with HDL-C (+3.3 mg/dL, P = 1.3 x 10 -8 ). rs3215707 occurs 125 (25%) loci displayed evidence of allelic heterogeneity at P < 5x10 -8 , 13 (81.3%) had at least 133 moderate evidence (P < 1x10 -4 ) of allelic heterogeneity ( Supplementary Table 8 ). Through 134 conditional analyses for LDL-C, we identified a low-frequency haplotype specific to African 135 Americans (MAF 0.1% FHS, 0% OOA, 1.0% JHS,) including variants in LD (r 2 > 0.8) at a 136 transcriptional transition region within the first intron of LDLR (rs17242843), LDLR promoter 137 (rs17249141), and enhancer 4kb upstream from the LDLR transcription start site (rs114197570) 138 ( Supplementary Fig. 5, Supplementary Fig. 6 ). Presence of these variants resulted in a 28 139 mg/dL lowering of LDL cholesterol (P = 2x10 -11 ), indicating a gain-of-function effect on LDLR 140 ( Supplementary Fig. 7) . 141
142

Rare variant association study of coding variants 143
Rare variants occur too infrequently to allow association tests of individual variants and thus, 144 require aggregating rare variants into sets and testing quantitative trait distribution among 145 carriers of a set versus non-carriers. 8 We aggregated coding sequence variants within each gene 146 that were predicted to lead to loss of function (e.g. nonsense, canonical splice-site, or frameshift) 147 or annotated as "disruptive" by the ensemble MetaSVM 9 in silico approach. The median 148 [interquartile range] combined MAF per gene was 0.25% [0.090-0.69%] ( Supplementary Fig.  149 8). To account for known bidirectional effects of disruptive mutations in some Mendelian 150 dyslipidemia genes, we accordingly used a mixed model sequence kernel association test 151 (SKAT). 10,11 Five genes associated with lipids at an exome-wide level (alpha = 0.05 / ~20,000 152 protein-coding genes = 2.5 x 10 -6 ) (LDLR, PCSK9, and APOE for LDL-C, LCAT for HDL-C, 153
and APOC3 for triglycerides). Each has been previously established as a cause of Mendelian 154 forms of dyslipidemia ( Supplementary Table 9 ). 155 156
Rare variant association study of non-coding variants 157
Next, we sought to determine whether rare variants in non-coding regions associate with plasma 158 lipids. We used four approaches to aggregate rare, non-coding variants. (Fig. 3) . First, we 159 aggregated variants within "sliding windows" of 3kb in length. 12,13 Second, we connected a non-160 coding variant to a gene if it resided in a segment annotated as an enhancer (and within 20kb of a 161 gene) or a region annotated as a promoter (and within 5kb of the transcription start site of a gene, 162 TSS). Third, using gene expression information we connected a non-coding variant to a gene if it 163 resided in a region annotated as an enhancer. Finally, we connected a non-coding variant to a 164 gene based on a model which predicted gene-enhancer pairs using a chromatin-state model that 165
we previously developed. 14 Regulatory annotations were derived from the ENCODE and NIH 166
Roadmap projects for two cell types -HepG2 and adipose nuclei -relevant to lipoprotein 167 metabolism. For these analyses, we consider a P < 0.05 / 254,032 groups = 2.0x10 -7 as significant 168
( Supplementary Table 10 , Supplementary Table 11 ). 169
Using the sliding window approach, we observed suggestive associations for 3kb 170 windows at the CETP (start chr16:56667000) locus (minimum P = 4x10 -6 ) and at the APOA1-171 APOC3 (start chr11:117094500) locus (minimum P = 8x10 -6 ) with HDL-C. 17.6% of non-172 coding sliding windows occurring within 1Mb of known lead lipid variants were at least 173 nominally (P < 0.05) associated with lipids versus 4.4% in other regions of the genome across all 174 traits (P difference = 8 x 10 -272 ). 175
An aggregation of rare non-coding variants at only two genes -LDLR and APOE -176 associated with LDL-C and total cholesterol (P < 2x10 -7 ) ( Supplementary Fig. 9 ) 177
( Supplementary Table 12 ). The strongest LDLR signal (P = 9.7x10 -11 ) was seen for an analysis 178 that connected enhancers and promoters to a gene based on physical proximity (approach #2 179 above). Closer inspection of the specific variants shows that this signal is driven by the low-180 frequency haplotype specific to African Americans that was described earlier (Supplementary 181 Table 12 ). The strongest APOE signal (P = 8.1x10 -26 ) was observed in 182 the model connecting enhancers to a gene by gene expression (approach #3 above). Accounting 183 for the strongest common variant association at the locus (rs7412, the APOE e2 isoform allele), 184 this signal attenuates to non-significance (P = 1.8x10 -2 ), suggesting that the non-coding variants 185 are driven by the APOE e2 isoform. Beyond these two results, we found no additional signals for 186 a burden of non-coding variants. 187 188
Contribution of monogenic and polygenic models to extreme LDL-C values 189
With the availability of sequence in both coding and non-coding regions in the same samples, we 190 estimated the simultaneous contribution of monogenic and polygenic determinants to extreme 191 LDL-C in individuals of European (EA) and African (AA) ancestry. We defined 'extreme' as the 192 top or bottom 5 th ancestry-specific percentile of LDL-C. Analyses were conducted in FHS and 193 MESA-EA subjects (extremes defined as LDL-C >183 mg/dl or LDL-C <72.9 mg/dl) and JHS 194 and MESA-AA subjects (extremes defined as LDL-C >198.6 mg/dl or LDL-C <71 mg/dl), 195
separately. 196
Among participants with extremely high LDL-C, we searched for mutations in any of six 197
Mendelian genes previously linked to high LDL-C (LDLR, APOB, PCSK9, ABCG5, ABCG8, and 198 LDLRAP1) ( Supplementary Table 13 ). 199
To determine polygenic contribution, we implemented a systematic approach to derive, 200 test, and validate a new 'genome-wide' polygenic score for LDL-C using mutually independent 201 datasets. A polygenic score provides a quantitative assessment of the cumulative risk associated 202 with multiple common risk alleles for each individual. Scores for each individual participant are 203 created by adding up the number of risk alleles at each variant and then multiplying the sum by 204 the literature-based effect size. 205
We derived a genome-wide polygenic score based on the association statistics of all 206 available common (MAF ≥ 0.01) SNPs with LDL-C, as determined by our previously published 207 genome-wide association study. 7 The correlation between the variants was assessed using the 208 European reference population from the 1000 Genomes study. 17 The LDPred computational 209 algorithm was then used to construct genome-wide polygenic scores. 15 This Bayesian approach 210 calculates a posterior mean effect size for each variant based on a prior (association with LDL-C 211 in a previously published study) and subsequent shrinkage based on the extent to which this 212 variant is correlated with similarly associated variants in a reference population. The underlying 213
Gaussian distribution additionally considers the fraction of causal (e.g. non-zero effect sizes) 214 markers. Because this fraction is unknown for any given disease, LDpred uses a range of 215 plausible values to construct different polygenic scores. We also applied various r2 and p-value 216 thresholds to the previously published results. As a comparison to the expanded polygenic 217 scores, we generated an additional polygenic score restricted to lead variants (P < 5x10 -8 ) at 218 distinct genomic loci, weighted by discovery beta (restricted score). The best score was 219 determined based on maximal model fit (R2) from a linear regression models in a health-care 220 biobank of 25,534 unrelated individuals (Nord-Trøndelag Health Study, HUNT) 16 221
( Supplementary Table 14 ). 222
For LDL-C, a genome-wide polygenic score incorporating 2 million single nucleotide 223 polymorphisms with LDpred provided the best model fit ( Supplementary Table 15 ). We 224 applied this polygenic score separately within the WGS samples in FHS, JHS, and MESA. We 225 labelled individuals as high polygenic score if they fell in the top 5 th percentile of race-specific 226 scores ( Table 1) . 227
Among EA participants, a monogenic mutation was associated with an odds ratio of 228 10.92 (95% CI 3.71-32.14) for extremely high LDL-C whereas a high polygenic score associated 229
with an odds ratio of 7.65 (95% CI 5.56-10.52). In EA individuals, those who carried a 230 monogenic mutation had 30 mg/dl higher LDL-C (when compared with non-carriers; P = 2.1x10 -231 4 ) and those who had a high polygenic score had 33 mg/dl greater LDL-C (when compared with 232 all others; P = 1.7x10 -57 ). Of 287 EA participants with extremely high LDL-C, 2% carried a 233 monogenic mutation and 23% had a high polygenic score. 234
Among AA participants, a monogenic mutation was associated with an odds ratio of 7.43 235 (95% CI 3.01-18.35) for extremely high LDL-C whereas a high polygenic score associated with 236 an odds ratio of 3.2 (95% CI 2.1-4.89). In AA individuals, those who carried a monogenic 237 mutation had 41 mg/dl higher LDL-C (when compared with non-carriers; p = 2.3x10 -7 ) and those 238 who had a high polygenic score had 17 mg/dl greater LDL-C (when compared with all others; P 239 = 6.4x10 -10 ). Of 217 AA participants with extremely high LDL-C, 3% carried a monogenic 240 mutation and 13% had a high polygenic score. 241
We replicated the association between a high polygenic score and extremely high LDL-C 242 in an independent sample, the ARIC cohort. Among ARIC-EA individuals, a high polygenic 243 score was associated with an odds ratio of 7.35 (95% CI 5.95-9.10; P < 2x10 -16 ) for extremely 244 high LDL-C and 42.8 mg/dl (95% CI 40.0-47.5; P < 2x10 -16 ) higher LDL-C compared with 245 individuals without a high polygenic score. Among ARIC-AA participants, a high polygenic 246
score was associated with an odds ratio of 2.7 (95% CI 1.77-4.09; P < 3.3x10 -6 ) for extremely 247 high LDL-C and a 23.2 mg/dl (95% CI 15.0-31.5; P = 3.8x10 -8 ) higher LDL-C compared with 248 individuals without a high polygenic score. 249
We analyzed the monogenic and polygenic contribution to extremely low LDL-C in EA 250 and AA participants and found similar patterns where monogenic mutations as well as a 251 polygenic score conferred similar effect sizes ( Table 1) . 252
253
Discussion 254
Here, we performed whole genome sequencing in 16,342 ethnically diverse individuals 255 and analyzed the incremental value of WGS for locus discovery and for clinical interpretation. 256
We replicated associations for 28 common variant loci previously associated with lipids in much 257 larger genome-wide association analyses. We identified an association for a low frequency 1-bp 258 deletion at 9p24.1 with HDL-C. While we replicated burden associations of rare coding 259 mutations at known Mendelian lipid genes, we did not detect any burden associations of rare 260 non-coding mutations through four different approaches. Lastly, we developed a new genome-261 wide polygenic score and showed that such a score confers an effect size on LDL-C similar to 262 carrying a monogenic mutation, but is also notable for a much greater frequency. 263
These results permit several conclusions. Using whole genome sequencing as a discovery 264 tool, the incremental yield of new loci was modest. In particular, despite a genome-wide search 265 using four different aggregation approaches and regulatory annotations from two relevant tissues, 266
we identified no burden-of-rare-variant signals in non-coding regions. Mutation target size and 267 natural selection pressure is smaller in non-coding regions when compared with coding regions; 268 based on these considerations, power calculations have suggested that sample sizes may need to 269 considerably larger to identify rare variant burden associations in non-coding regions. 8 270
Of great interest, we observed that the relative contribution of polygenic score to 271 extremely high LDL-C is considerably greater than monogenic mutations. For example, in EA 272 individuals, both high polygenic score and a monogenic mutation confer similar effects (~30 273 mg/dl higher LDL-C) but a high polygenic score in present in 23% of participants with 274 extremely high LDL-C whereas a monogenic mutation is present in only 2%. In most individuals 275 who carry diagnosis of familial hypercholesterolemia, no monogenic mutation is identified with 276 clinical exome sequencing 17,18 ; for a large fraction of these 'mutation-negative' familial 277 hypercholesterolemia, high polygenic scores may be operative. 278
Important caveats and limitations should be considered. First, appropriate definitions of 279 statistical significance for WGS association analyses have not been harmonized in the field. The 280 convention of alpha=5x10 -8 comes from the assumption of performing 1,000,000 independent 281 tests. Based on our findings and simulations from others 3 , 10 -9 may be more appropriate for 282 analyses across diverse ethnicities to allele frequency 0.1%. Second, power is somewhat 283 diminished with our rare variant meta-analysis approach to combine P values with Fisher's 284 method. Given known diverse coding mutations within Mendelian genes with bidirectional 285 effects and the inability to assume unidirectional effects within the non-coding space, we 286 employed a SKAT statistical framework. Prior approaches leveraging covariance matrices for 287 SKAT meta-analysis were computationally inefficient for the dataset and multiple grouping 288 strategies. 19, 20 Thus, our approach is conservative. Third, the polygenic scores described here 289 were derived from genome-wide association studies performed largely in EA ancestry 290 participants. 7 Because allele frequencies, linkage disequilibrium patterns, and effect sizes of 291 common polymorphisms vary by ancestry, the predictive capacity of polygenic score was 292 attenuated in non-European ancestry individuals. 21 . This is an important limitation for the field 293 that requires efforts to characterize common genomic variation influencing complex traits among 294
non-Europeans. 295
In summary, we present a large-scale WGS analysis of plasma lipids in 16,324 ethnically 296 diverse participants. Common, non-coding variants and rare, coding variants contribute to 297 plasma lipid variation; however, association signals for rare, non-coding mutations were not 298 detectable. calling across studies. In brief, sequence data were received from each sequencing center in the 411 form of bam files mapped to the 1000 Genomes hs37d5 build 37 decoy reference sequence. 412
Processing was coordinated and managed by the 'GotCloud' processing pipeline. 22 413
The two sequence quality criteria were used in order to pass sequence data on for joint 414 variant discovery and genotyping are: estimated DNA sample contamination below 3%, and 415 fraction of the genome covered at least 10x 95% or above. DNA sample contamination was 416 estimated from the sequencing center read mapping using software verifyBamId. 23 417
The genotype call sets used for analysis are from "freeze 3a" of the variant calling Quality Score Recalibration. Additionally, genotypes with GQ<20, DP<10 or >200, and poor 466 allele balance (homozygous with <0.90 supportive reads or heterozygous with <0.20 supportive 467 reads) were removed. And variants within low complexity regions were removed across all 468 samples. 30 Variants with >5% missing calls, quality by depth <2 (SNPs) or <3 (indels), 469
InbreedingCoeff <-0.3, and pHWE <1x10 -9 (within each cohort) were filtered out. 470
Annotation 471
Variants were annotated with Hail using annotations from Ensembl's Variant Effect 472
Predictor 31 for protein-coding annotations and Reg2Map HoneyBadger2-intersect for regulatory 473 annotations at DNase I regions -log 10 (P) >= 10 474 (https://personal.broadinstitute.org/meuleman/reg2map/HoneyBadger2-intersect_release/). 475
Traits 476
Conventionally measured plasma lipids, including total cholesterol, LDL-C, HDL-C, and 477 triglycerides, were included for analysis. LDL-C was either calculated by the Friedwald equation 478 when triglycerides were <400 mg/dl or directly measured. Given the average effect of statins, 479 when statins were present, total cholesterol was adjusted by dividing by 0.8 and LDL-C by 480 dividing by 0.7, as previously done. 32 Triglycerides were natural log transformed for analysis. 481
Single variant association analysis 482
Single variant analysis was performed in EPACTS with Efficient Mixed-Model 483
Association eXpedited (EMMAX) for associating each variant site with each lipid outcome 484 within each jointly called variant call file (VCF). 10 The results were meta-analyzed for each trait 485 using the METAL software. All analyses were adjusted for age, age 2 , sex, cohort, and an 486 empirically derived kinship matrix to account for both familial and more distant relatedness. For 487 the TOPMed Phase I VCF, which included OOA, LDL-C and total cholesterol analyses were 488 also adjusted for APOB p.R3527Q and triglycerides and HDL-C analyses were also adjusted for 489 APOC3 p.R19Ter. To ensure robust results, we only performed single variant analysis for 490 variants with a MAF > 0.1%. Variants were meta-analyzed across all three VCFs using 491 METAL. 33 Summary statistics only for variants with MAF > 0.1% for the given VCF were 492 included in the meta-analysis. Statistical significance alpha of 5x10 -8 was used for these 493
analyses. 494
For loci with at least one variant with P<5x10 -8 within the TOPMed Phase I VCF, 495
iterative conditional association analysis was performed. Iterative conditioning was performed 496 until P>1x10 -4 was attained. 497
Rare variant association analyses 498
Coding 499
We first identified rare (MAF <1%) mutations for each VCF within coding sequences. 500
After Variant Effect Predictor 31 annotation, we identified loss-of-function (e.g. nonsense, 501 canonical splice-site, and frameshift) and disruptive missense (by MetaSVM 9 ). 502
Sliding window 503
We also performed rare variant association tests within the non-coding space 504 Figure 7) . As before, we performed a "sliding window" approach aggregating 505 3kb (overlapping by 1.5kb) windows and considering rare variants occurring within enhancer or 506 promoter elements at DNase I hypersensitivity sites. 507
(Supplementary
Proximity to transcription start sites 508
For non-coding tests, we next attempted to link rare non-coding variants with genes for 509 association testing using regulatory annotations for HepG2 and adipose nuclei from ENCODE 510 and NIH Roadmap. Given prior observations showing enrichment of functional promoter 511 variants at LIPG with HDL-C extremes 34 , we similarly aggregated variants near transcription 512 start sites (TSS). Prior studies have shown that approximately 80% of cis-eQTLs fall within 513 100kb of TSS. 35 To increase likelihood that of mapping regulatory variants to the nearest gene, 514
we were more restrictive and included variants overlapping promoter sequences +/-5kb and 515 enhancer sequences +/-20kb of TSS at DNase I hypersensitivity sites. 516
Linking enhancers to genes by gene expression 517
We also linked chromatin state defined enhancers with genes using data from the 518 Roadmap Epigenomics project 36 and the method presented previously 37 with a few small 519 modifications. 38 The method predicts links using chromatin state information, position of the 520 enhancer relative to the TSS, and the correlation of multiple chromatin marks with gene 521 expression across cell types. Here we used the correlation with gene expression of the signal of 522 five chromatin marks: H3K27ac, H3K9ac, H3K4me1, H3K4me2, and DNaseI hypersensitivity. 523
The gene expression data was the RPKM expression data for protein coding exons across 56 524 reference epigenomes from the Roadmap Epigenomics project (available in the file 525 57epigenomes.RPKM.pc from http://compbio.mit.edu/roadmap; Universal Human Reference 526 was excluded). The chromatin mark signal was the -log 10 (P) tracks averaged to a 200-bp 527 resolution. As input to our code we used the version of those tracks first averaged at 25-bp 528 resolution using the 'Convert' command of ChromImpute. 39 In computing correlation between a 529 specific chromatin mark signal and gene expression we used the Pearson correlation and omitted 530 from the calculation samples lacking both chromatin mark signal and gene expression data. We 531 made predictions separately for each of the 127 reference epigenomes and locations assigned to 532 chromatin states, 6_EnhG, 7_Enh, and 12_EnhBiv, of the 15-state core 5-marks ChromHMM 533
To connect noncoding variants with putative target genes, we predicted functional gene-557 enhancer pairs using a chromatin state-based model we previously developed. 14 This model 558 assumes that the impact of an enhancer on gene expression is determined by the product of its 559 intrinsic "Activity" (for which we use quantitative DNase-Seq and H3K27ac ChIP-Seq levels as 560 a proxy) and the "Contact Frequency" at which the enhancer physically encounters its target 561 promoter in the nucleus (for which we use Hi-C data as a proxy). We previously found such an 562
Activity by Contact (ABC) model accurately identifies enhancers whose perturbation leads to 563 changes in gene expression in the human MYC locus 14 , and we have since found that the same 564 model can identify enhancers across other gene loci and cell types (C. Fulco, E. Lander, and J. 565
Engreitz, in preparation). We extended our previously published model to predict enhancer-gene 566 connections in the liver, using DNase-Seq and H3K27ac ChIP-Seq data from a hepatocarcinoma 567 cell line (HepG2) previously generated by the ENCODE project. 42 To define putative regulatory 568 elements, we expanded DNase-Seq peak calls from ENCODE by 500 bp on either side and 569 merged overlapping peaks. 14 For each element, we calculated Activity as a function of the 570 normalized read count of H3K27ac and DNase-Seq. Because high-resolution Hi-C data is not 571 available for HepG2 cells, we estimated the Contact probability between putative regulatory 572 elements and genes using the average profile across deeply sequenced Hi-C libraries from 7 573 different cell types 43 as previously described 14 . For each putative enhancer-gene pair, we 574 calculated an "ABC score" equal to the Activity × Contact of the putative enhancer normalized 575 by the sum of Activity × Contact across all other putative elements within 5 Mb of the target 576 gene. We tuned free parameters in this model (such as the relative weight of DNase-Seq and 577
H3K27ac data and a pseudocount to add to Hi-C data) and chose a threshold cutoff using a set of 578 experimentally measured enhancer-promoter connections in two cell types (C. Fulco, E. Lander, 579 and J. Engreitz, in preparation). This analysis defined, for each expressed gene, a set of elements 580 predicted to regulate that gene in HepG2 cells. These sets of elements were used for gene-level 581 variant burden tests. 582
Statistical test 583
We tested the association of the aggregate of the aforementioned groupings with each 584 lipid trait using the mixed-model Sequence Kernal Association Test (SKAT) implementation in 585 EPACTS to account for bidirectional effects. 10 Analyses were adjusted for age, age 2 , sex, cohort, 586 and empiric kinship. P values were meta-analyzed using Fisher's method. Statistical significance 587 for each gene-based test was 0.05 / 20,000 tests = 2.5x10 -6 . 588
Lipid extremes analysis 589
Traits 590
We first defined LDL-C extremes as the top and bottom ancestry-specific 5 th percentiles 591 from the data (LDL-C > 183 mg/dl or > 198.6 mg/dl for EA and AA, respectively; LDL-C < 72.9 592 mg/dl or <71 mg/dl for EA and AA, respectively). 593
Monogenic determinants 594
We catalogued mutations in Mendelian genes previously linked to extreme LDL-C 595
( Supplementary Table 13 ). We included variants that were previously linked to Mendelian 596 dyslipidemia in ClinVar ("pathogenic" or "likely pathogenic" with no "benign") or loss-of-597 function, and had an allele frequency <1% (autosomal dominant) or <10% (autosomal recessive). 598
Genotypes were only considered based on expected inheritance pattern (autosomal dominant or 599 autosomal recessive). 600
Polygenic score derivation 601
